Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany.

Cancer Clinical trials Molecular profiling Personalized medicine Precision medicine

Journal

Seminars in cancer biology
ISSN: 1096-3650
Titre abrégé: Semin Cancer Biol
Pays: England
ID NLM: 9010218

Informations de publication

Date de publication:
09 2022
Historique:
received: 28 10 2020
accepted: 18 05 2021
pubmed: 26 5 2021
medline: 1 7 2022
entrez: 25 5 2021
Statut: ppublish

Résumé

Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.

Identifiants

pubmed: 34033893
pii: S1044-579X(21)00156-5
doi: 10.1016/j.semcancer.2021.05.026
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

242-254

Investigateurs

Anna Lindstrand (A)
Anna Wedell (A)
David Gisselsson (D)
Erik Melén (E)
Gisela Helenius (G)
Hans Ehrencrona (H)
Lars Engstrand (L)
Lars Palmqvist (L)
Lars-Åke Levin (LÅ)
Lovisa Lovmar (L)
Maréne Landström (M)
Martin Hallbeck (M)
Mia Wadelius (M)
Per Sikora (P)
Ambros J Beer (AJ)
Anna L Illert (AL)
Jan Budczies (J)
Konstantin Nikolaou (K)
Oliver Kohlbacher (O)
Peter Horak (P)
Peter Kuhn (P)
Christopher Schroeder (C)
Melanie Boerries (M)
Silke Lassmann (S)
Verena I Gaidzik (VI)

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Albrecht Stenzinger (A)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany. Electronic address: albrecht.stenzinger@med.uni-heidelberg.de.

Anders Edsjö (A)

Department of Clinical Genetics and Pathology, Office for Medical Services, Region Skåne, Lund, Sweden; Genomic Medicine Sweden (GMS), Sweden. Electronic address: anders.edsjo@skane.se.

Carolin Ploeger (C)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.

Mikaela Friedman (M)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Genomic Medicine Sweden (GMS), Sweden.

Stefan Fröhling (S)

Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.

Valtteri Wirta (V)

Department of Microbiology, Tumor and Cell Biology, Clinical Genomics Facility, Science for Life Laboratory, Karolinska Institutet, Solna, Sweden; Genomic Medicine Sweden (GMS), Sweden.

Thomas Seufferlein (T)

Department of Internal Medicine I, University of Ulm, Ulm, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.

Johan Botling (J)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Genomic Medicine Sweden (GMS), Sweden.

Justus Duyster (J)

Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.

Michael Akhras (M)

Department of Microbiology, Tumor and Cell Biology, Clinical Genomics Facility, Science for Life Laboratory, Karolinska Institutet, Solna, Sweden; Genomic Medicine Sweden (GMS), Sweden.

Robert Thimme (R)

Department of Medicine II, University Medical Center, Freiburg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.

Thoas Fioretos (T)

Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden; Genomic Medicine Sweden (GMS), Sweden.

Michael Bitzer (M)

Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.

Lucia Cavelier (L)

Medical Genetics and Genomics, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Genomic Medicine Sweden (GMS), Sweden.

Peter Schirmacher (P)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.

Nisar Malek (N)

Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.

Richard Rosenquist (R)

Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden; Genomic Medicine Sweden (GMS), Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH